What is IDEAYA Biosciences, Inc.'s deferred revenue?

IDEAYA Biosciences, Inc. (IDYA) reported deferred revenue of $490K in Q3 2025.

What is the long-term trend for IDEAYA Biosciences, Inc.'s deferred revenue?

Over 2 years (2020 to 2022), IDEAYA Biosciences, Inc.'s deferred revenue has grown at a -44.3% compound annual growth rate (CAGR), from $27.61M to $8.57M.

What does deferred revenue mean?

Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.

IDEAYA Biosciences, Inc. IDYA Deferred Revenue

Deferred Revenue at other companies

Arcus BiosciencesRCUS

$34M-52.8%

ImmunomeIMNM

$0-100%

Nuvation BioNUVB

$8.65M-19.7%

Stoke Therapeutics, Inc.STOK

$6.6M-35.6%

Sarepta Therapeutics, Inc.SRPT

$116.04M+159%

BioCryst PharmaceuticalsBCRX

$5.41M—

Other financials

Income statement

See full

Revenue$6.6M—

Operating income-$108.5M-28.6%

Net income-$98.5M-36.5%

EPS (diluted)-$1.11-35.4%

Balance sheet

See full

Cash & equivalents$157.5M+21.2%

Total debt$28.6M+10.1%

Total equity$937.3M-8.5%

Total assets$1.0B-6.4%

Cash flow

See full

Operating cash flow-$75.2M-24.6%

CapEx$967.0K-27.3%

Free cash flow-$76.1M-23.5%

Valuation

See full

Market cap$3.36B+104%

Enterprise value$3.23B+110%

P/S14.5×+9.9×

Profitability

See full

Operating margin-4,671.1%-5,434pp

Net margin-3,921.1%-4,562pp

FCF margin-3,592%-4,290pp

Returns & leverage

See full

Return on equity-14.3%-5.0pp

Debt / equity0×0.0×

Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed November 4, 2025, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s deferred revenue?: IDEAYA Biosciences, Inc. (IDYA) reported deferred revenue of $490K in Q3 2025.
What is the long-term trend for IDEAYA Biosciences, Inc.'s deferred revenue?: Over 2 years (2020 to 2022), IDEAYA Biosciences, Inc.'s deferred revenue has grown at a -44.3% compound annual growth rate (CAGR), from $27.61M to $8.57M.
What does deferred revenue mean?: Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.